Healthcare shares split between US progress and cash-raising pain

• Noxopharm fell 28.57% after proposing new shares and converting A$3.78 million of notes.
• Pacific Edge rose 25.53% after Medicare confirmed coverage for its bladder cancer tests.
• Mayne Pharma climbed 21.26% after agreeing to sell its international arm for $55.5 million.
• Radiopharm and Proteomics International fell despite progress towards trials and commercial launches.